Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

MAPT-protokoll: Fiksering versus artroplastikk kirurgiske behandlinger for tidlig rekonvalesens etter hoftebrudd (FASTER-HIP) (FASTER-HIP)

5. november 2026 oppdatert av: Joseph Patterson, University of Southern California

Musculoskeletal Adaptiv Plattformstudie (MAPT): Fiksasjon versus Artroplastikk Kirurgiske Behandlinger for Tidlig Restitusjon etter HOFTEbrudd (FASTER-HIP)

This study is an intervention domain of the Musculoskeletal Adaptive Platform Trial. The primary goal of this pragmatic, randomized, open-label, comparative effectiveness trial is to evaluate if arthroplasty is superior to internal fixation when used to treat minimally displaced femoral neck fractures in older adults ≥60 years old. We hypothesize that arthroplasty will reduce death, preserve ambulation, increase days alive and out of hospital, and improve health status compared to internal fixation within 4 months and 12 months from randomization.

Studieoversikt

Detaljert beskrivelse

The Musculoskeletal Adaptive Platform Trial (MAPT) is an adaptive platform trial protocol that enables the simultaneous evaluation of multiple interventions (i.e., intervention domains) within a consistent infrastructure. Each intervention being evaluated in the MAPT will have an intervention domain protocol that describes additional eligibility criteria, interventions, secondary outcomes, and statistical stopping rules. The overarching objective of the MAPT trial platform is to incrementally decrease decisional uncertainty and identify treatments that will optimize patient outcomes. The platform focuses on the comparative effectiveness of available treatment options.

Adult patients aged 60 years or older with a low-energy minimally displaced femoral neck fracture treated with surgery are eligible for the FASTER-HIP intervention domain. Nearly half of all elderly hip fractures are femoral neck fractures, and approximately 20% are minimally displaced. Internal fixation has remained the treatment of choice for these injuries because these fractures can be fixed in situ, and the surgical implants can be inserted with little surgical dissection. Patients treated with internal fixation experience high complication rates, with the pooled risk of reoperation and mortality each above 14%. Preliminary data have suggested arthroplasty for minimally displaced fractures may lead to better patient outcomes, including improved ambulation, fewer reoperations, and a lower risk of death compared to internal fixation. While the preliminary data supporting the use of arthroplasty for minimally displaced fractures is promising, the necessary evidence to make this practice change remains lacking.

FASTER-HIP is a pragmatic, randomized, open-label, comparative effectiveness trial comparing hip arthroplasty versus internal fixation for minimally displaced femoral neck fractures. Randomization in this domain occurs in a 1:1 ratio (hip arthroplasty:internal fixation). The primary outcome is a composite of death within 120 days, ambulation status at 120 days, and days alive and out of hospital within 120 days of randomization. The primary outcome will be hierarchically assessed using the Win ratio. Secondary outcomes include the same composite at 365 days, individual components of the composite, health-related quality of life (EQ-5D-5L), and pain scores during hospitalization.

Studietype

Intervensjonell

Registrering (Antatt)

600

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Ottawa, Canada, K1H 8L6
        • Har ikke rekruttert ennå
        • The Ottawa Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bradley Meulenkamp, MD
    • British Columbia
      • Vancouver, British Columbia, Canada, V6T 1Z4
        • Rekruttering
        • University of British Columbia
        • Ta kontakt med:
          • Aresh Sepehri, MD
        • Ta kontakt med:
        • Hovedetterforsker:
          • Aresh Sephri, MD
      • Vancouver, British Columbia, Canada
        • Rekruttering
        • Fraser Health Authority
        • Ta kontakt med:
        • Ta kontakt med:
          • Telefonnummer: 604-777-5577
        • Hovedetterforsker:
          • Darius Viskontas, MD
    • Ontario
      • London, Ontario, Canada, N6A 5W9,
        • Rekruttering
        • London Health Sciences Centre
        • Ta kontakt med:
        • Hovedetterforsker:
          • Emil Schemitsch, MD
    • California
      • Irvine, California, Forente stater, 92660
        • Rekruttering
        • University of California, Irvine
        • Hovedetterforsker:
          • Gerard Slobogean, MD
        • Ta kontakt med:
      • Los Angeles, California, Forente stater, 90048
        • Rekruttering
        • Cedars-Sinai Medical Center
        • Hovedetterforsker:
          • Carol Lin, MD
        • Ta kontakt med:
      • Los Angeles, California, Forente stater, 90033
        • Rekruttering
        • University of Southern California
        • Hovedetterforsker:
          • Joshua L Gary, MD
        • Ta kontakt med:
      • Los Angeles, California, Forente stater, 90033
        • Rekruttering
        • Los Angeles General Medical Center
        • Hovedetterforsker:
          • Joshua L Gary, MD
        • Ta kontakt med:
      • San Francisco, California, Forente stater, 94143
        • Rekruttering
        • University of California San Francisco
        • Hovedetterforsker:
          • Saam Morshed, MD
        • Ta kontakt med:
    • Florida
      • Miami, Florida, Forente stater, 33146
        • Har ikke rekruttert ennå
        • University of Miami
        • Ta kontakt med:
        • Hovedetterforsker:
          • Giselle Hernandez, MD
    • Indiana
      • Bloomington, Indiana, Forente stater, 47405
        • Rekruttering
        • Indiana University
        • Hovedetterforsker:
          • Dillon O'Neill, MD
        • Ta kontakt med:
    • Maryland
      • Baltimore, Maryland, Forente stater, 21201
        • Rekruttering
        • University of Maryland, Baltimore - R Adams Cowley Shock Trauma Center
        • Hovedetterforsker:
          • Mark Gage, MD
        • Ta kontakt med:
      • Largo, Maryland, Forente stater, 20774
        • Rekruttering
        • University of Maryland Capital Region Health
        • Hovedetterforsker:
          • Todd Jaeblon, MD
        • Ta kontakt med:
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Har ikke rekruttert ennå
        • Beth Israel Deaconess Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ishaq Ibrahim, MD
      • Boston, Massachusetts, Forente stater, 02115
        • Rekruttering
        • Massachusetts General Brigham
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michael Weaver, MD
    • Mississippi
      • University, Mississippi, Forente stater, 38677
        • Rekruttering
        • University of Mississippi
        • Hovedetterforsker:
          • Patrick Bergin, MD
        • Ta kontakt med:
    • New York
      • New York, New York, Forente stater, 10016
        • Rekruttering
        • NYU Langone Health
        • Hovedetterforsker:
          • Ran Schwarzkopf, MD
        • Ta kontakt med:
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45221
        • Rekruttering
        • University of Cincinnati
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michael Beltran, MD
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73104
        • Rekruttering
        • University of Oklahoma Health Sciences Center
        • Hovedetterforsker:
          • Brandon Hull, MD
        • Ta kontakt med:
    • Pennsylvania
      • Allentown, Pennsylvania, Forente stater, 18102
        • Rekruttering
        • St. Luke's University Health System
        • Hovedetterforsker:
          • Dustin Greenhill, MD
        • Ta kontakt med:
    • South Carolina
      • Greenville, South Carolina, Forente stater, 29601
        • Rekruttering
        • Prisma Health-Upstate
        • Hovedetterforsker:
          • Kyle Jeray, MD
        • Ta kontakt med:
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37235
        • Rekruttering
        • Vanderbilt University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Lauren Tatman, MD
    • Utah
      • Salt Lake City, Utah, Forente stater, 84108
        • Rekruttering
        • University of Utah
        • Hovedetterforsker:
          • Lucas Marchand, MD
        • Ta kontakt med:
    • Vermont
      • Burlington, Vermont, Forente stater, 05405
        • Har ikke rekruttert ennå
        • University of Vermont
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michael Blankstein, MD
    • Virginia
      • Fairfax, Virginia, Forente stater, 22031
        • Rekruttering
        • Inova Health Care Services
        • Hovedetterforsker:
          • Greg Gaski, MD
        • Ta kontakt med:
    • Wisconsin
      • Madison, Wisconsin, Forente stater, 53706
        • Rekruttering
        • University of Wisconsin - Madison
        • Hovedetterforsker:
          • Chris Domes, MD
        • Ta kontakt med:
      • Grålum, Norge, 1714
        • Rekruttering
        • Sykehuset Østfold HF / Østfold Hospital Trust
        • Ta kontakt med:
          • Frede Frihagen, MD
        • Ta kontakt med:
        • Hovedetterforsker:
          • Frede Frihagen, MD
      • Barcelona, Spania
        • Har ikke rekruttert ennå
        • Hospital Universitari Vall d'Hebron
        • Ta kontakt med:
        • Hovedetterforsker:
          • Carlos Alberto Piedra-Calle, MD
      • Barcelona, Spania
        • Har ikke rekruttert ennå
        • Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG)
        • Hovedetterforsker:
          • Alfred Dealbert, MD
        • Ta kontakt med:
      • Barcelona, Spania, 08221
        • Har ikke rekruttert ennå
        • Hospital Universitario Mutua de Terrassa
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pablo Castillon Bernal, MD
      • Barcelona, Spania
        • Har ikke rekruttert ennå
        • FRCB-IDIBAPS (Hospital Clinic Barcelona)
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pilar Camacho, MD
      • Edinburgh, Storbritannia, EH8 8BG

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

60 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • 60 years of age or older undergoing surgery due to a minimally displaced femoral neck fracture
  • The patient has a health condition affecting physical mobility.
  • Complete fracture of the femoral neck (AO/OTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging.
  • Minimally displaced fracture that could be, in the judgment of the attending surgeon, managed with either arthroplasty or in situ internal fixation without reduction.
  • Low energy injury mechanism.
  • Surgeons with expertise in internal fixation and total hip arthroplasty or hemiarthroplasty are available to perform surgery.

Exclusion Criteria:

  • The patient is not clinically suitable for either compared treatment.
  • Expected injury survival of less than 12 months.
  • Terminal illness with expected survival of less than 12 months.
  • Incarceration.
  • Unable to obtain informed consent due to language barriers.
  • Unable to obtain informed consent because the legally authorized representative was unavailable.
  • Problems, in the judgment of the study personnel, with maintaining follow-up with the patient.
  • Currently enrolled in a study or intervention domain that does not permit co-enrollment.
  • Prior enrollment in the specific platform trial intervention domain.
  • Patient or legally authorized representative did not provide informed consent (declined participation).
  • Eligible patient or legally authorized representative was not approached within the screening window (missed participant).
  • Other reasons to exclude the patient, as approved by the data coordinating center.
  • Associated lower extremity injury that prevents post-operative weight-bearing.
  • Retained hardware around the hip that precludes either study treatment.
  • Infection around the hip (soft tissue or bone).
  • Pathologic fracture with a lytic lesion in the femoral neck that precludes internal fixation.
  • Injury did not occur within 21 days of screening.
  • Patient is too ill, in the judgment of the attending surgeon, for internal fixation.
  • Patient is too ill, in the judgment of the attending surgeon, for arthroplasty.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Hofteprotese

Participants will undergo surgical treatment using standard hip arthroplasty techniques for femoral minimally displaced femoral neck fracture. A modern porous-coated press-fit or cemented hip arthroplasty prosthesis will be used at the treating surgeon's discretion. Press-fit implants that have no ingrowth or ongrowth surface will not be permitted. The type of hip prosthesis (hemiarthroplasty or total hip arthroplasty), bearing (single or dual mobility), or the method of arthroplasty fixation (cemented or uncemented) will be at the discretion of the treating surgeon.

Aktiv komparator: Intern fiksering

Participants will undergo surgical treatment using standard fixation techniques for minimally displaced femoral neck fractures. The treating surgeon may perform fracture reduction maneuvers if desired. Fixed-angle devices and multiple screws will be permitted. The internal fixation device(s) will be inserted through a small lateral incision. Internal fixation constructs combining cancellous screws and fixed-angle devices will be permitted.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Composite outcome of death, ambulation status, and days alive and out of hospital.
Tidsramme: 120 days after randomization

Death consists of time to all-cause mortality.

Ambulation will be evaluated using an ordinal ranking of independence.

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
120 days after randomization

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Composite outcome of death, ambulation status, and days alive and out of hospital.
Tidsramme: 365 days after randomization

Death consists of time to all-cause mortality.

Ambulation will be evaluated using an ordinal ranking of independence.

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
365 days after randomization
Death
Tidsramme: 120 days post-randomization

Death consists of time to all-cause mortality.

120 days post-randomization
Death
Tidsramme: 12 months post-randomization

Death consists of time to all-cause mortality.

12 months post-randomization
Ambulation status
Tidsramme: 120 days post-randomization

Ambulation will be evaluated using an ordinal ranking of independence

120 days post-randomization
Ambulation status
Tidsramme: 12 months post-randomization

Ambulation will be evaluated using an ordinal ranking of independence

12 months post-randomization
Days alive and out of hospital
Tidsramme: 120 days post-randomization

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
120 days post-randomization
Days alive and out of hospital
Tidsramme: 12 months post-randomization

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
12 months post-randomization
Health-related quality of life
Tidsramme: 120 days days post-randomization

EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health

120 days days post-randomization
Health-related quality of life
Tidsramme: 12 months post-randomization

EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health

12 months post-randomization
Numeric Pain Rating Scale
Tidsramme: During hospitalization in the first seven postoperative days

The highest level of pain recorded daily in the participant's medical record - Range: 0-10, higher score indicates higher level of pain

During hospitalization in the first seven postoperative days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Joseph T Patterson, MD, University of Southern California

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

23. januar 2026

Primær fullføring (Antatt)

28. februar 2029

Studiet fullført (Antatt)

31. januar 2030

Datoer for studieregistrering

Først innsendt

31. oktober 2025

Først innsendt som oppfylte QC-kriteriene

19. november 2025

Først lagt ut (Faktiske)

24. november 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. november 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere